(UroToday.com) Prostate cancer screening guidelines for men with germline BRCA alterations are not well established. The one completed study in this space was the IMPACT (Identification of Men with a genetic Predisposition to prostate Cancer: Targeted screening in men at higher genetic risk and controls”1. This study, implemented before prostate MRI became routinely implemented, found that germline BRCA2 carriers had a higher incidence of prostate cancer (19.4 cases per 1000 person-years versus 12 in non-carriers), were diagnosed at a younger age (61 versus 64 in non-carriers), and were more likely to have clinically significant tumors. BRCA1 alterations did not confer any detected differences in tumor incidence or characteristics.